Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 11/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 8/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28044582 | 0.84 | KDM5A (0.45) | KDM5AKDM4CKDM5CKDM5BPHF8 | |
| SCHEMBL21380036 | 0.78 | CNR1 (0.51) | ALDH1A1 | |
| SCHEMBL11801962 | 0.74 | EPHX1 (0.36) | CASP2EPHX1DNM1NAAA | |
| SCHEMBL11782041 | 0.73 | EPHX1 (0.39) | CASP2EPHX1DNM1NAAA | |
| SCHEMBL11312871 | 0.73 | EPHX1 (0.39) | CASP2EPHX1DNM1NAAA | |
| SCHEMBL3154015 | 0.72 | GPR84 (0.49) | ALDH1A1 | |
| SCHEMBL3286703 | 0.71 | ZDHHC20 (0.47) | CASP2EPHX1DNM1NAAA | |
| SCHEMBL3279969 | 0.71 | EPHX1 (0.37) | ALDH1A1CASP2EPHX1DNM1NAAA | |
| SCHEMBL22558106 | 0.71 | EPHX2 (0.52) | — | |
| SCHEMBL20515076 | 0.71 | ALDH1A1 (0.56) | ALDH1A1KDM5AKDM4CKDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008274-B2 | P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | MERCK SHARP & DOHME CORP. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306010-A1 | P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS | P2RY1, P2RY4, P2RY2 | ALDH1A1 1771/4885KDM5A 3834/4885KDM4C 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.